RNXT RenovoRx Inc

$RNXT Man I swear this reminds me SO much of the way $ABCL acted 6 months ago.. I know they are two totally different animals, but this has such a strong base and I truly believe our days will come!!!!!!!!!

$RNXT between this and my $ABCL, it’s been a damn good day so far. These are my two favorite holdings.

$RNXT still massively undervalued… seen far worse companies valued at the equivalent of 5-7 per share, so this is undervalued by any imaginable standards by a lot…

$RNXT stock bottom guys just need volume and this could fly over 2 fast soon this a 3 dollar plus stock this month gl

$RNXT TAMP is a localized drug-delivery platform designed to concentrate chemotherapy at the tumor site, including tumors with limited blood supply. By reducing systemic chemotherapy exposure, it may significantly improve patients’ quality of life. I also see TAMP as a potentially valuable platform for combining localized chemotherapy with checkpoint inhibitors and immunotherapies such as $IBRX ANKTIVA. IMO.

$RNXT bull thesis is a regime-transition thesis, not a momentum trade. Q2: $909K revenue (+61% QoQ), ~84% GM, 21 active centers, 63-center funnel, repeat orders, FY26 guide $3.75–4.25M. TIGeR-PaC is fully enrolled with 78/86 events already reached as of Aug 11. Financing is becoming asymmetric: 5.32M milestone warrants at ~$1.75/$1.93 are ITM near current levels. Cash exercise could bring ~$9.3M non-debt capital. If quarterly product sales hit $1.5M, accelerated expiry compresses holder optionality and can force the exercise decision. So the path is: commercial growth → higher utilization → $1.5M quarter → warrant monetization → runway extension → lower financing risk. The current retrace into ~$1.93–$2.00 is therefore a structural retest of the warrant/support zone, not automatically thesis failure. If RNXT holds this zone and Q3 confirms commercial acceleration, the next re-rating leg can be driven by fundamentals rather than speculation. Commercial medtech $RNXT

$RNXT investors nice run for a penny stock over a month now but the end of this run may be near. investors this stock was pump up by some major groups and we see a reversal coming to take this back down to mid dollar ranges . investors pump and dump stocks never last long and right now this is way over value it's book value.

$RNXT good morning my friends RNXT added to my watch list today because i see a growing BIO company with some huge things in the pipe line that i believe will send RNXT up in a big way. MY friends my pick for the next small bio company to past that $10 mark plus i do see this could happen very fast for this company as many price targets are around $14 which is not out of the question with what i am seeing and happening with this company getting on a ground floor of a BIO company is the key. I DO see this stock price heading higher this month with big news events coming. have a blessed day and week of trading.

$RNXT I like what I’m reading here I parked some money here today for a while Y’all don’t go to selling on me now. Stock has great potential. 

$RNXT I’ve been collecting more and more at this number and it is now my second biggest holding!

$RNXT bottom stock here guys added another 5k let see how this play out rest of SEPT gl

$RNXT maybe get some shares cheap today i be watching and adding here for sure later guys

$RNXT one last point the last day of this event will be tomorrow my friends hearing company has had a good event and meet with some very promising people in the PHAR area. have a blessed day

$RNXT GOOD morning RNXT a growing BIO company with some big things coming this year for this company with big news. my friends now hearing good things are happening with the GLOBAL conference event in NEW YORK this week which will run through the 15th. my friends i do see some huge move up in price coming in 2026 for RNXT and would not be surprise to see a news update how well this conference went sometime this week. have a blessed day and week of trading

$RNXT The most important thing is not selling... of course I'm not selling, I'm sitting comfortably at 1.15 average and wouldn't sell if it reached 0.5 because it can jump a lot more... so that's not even a point, but buying more at these prices when we know as a fact that this will reach 4-5 is clearly something to be done...

$RNXT I bought this one earlier this year ~20k shares, and it has performed quite well. Expected readout 2H 2027. P3 TIGeRPaC is moving along well, with a peer-reviewed PK/PD sub-study from TIGeR-PaC reporting that about 51% of the chemotherapy drug was extracted at the tumor site, supporting the logic that TAMP/RenovoCath can concentrate treatment locally while limiting systemic exposure. This is encouraging, although it is not the same as demonstrating an overall survival benefit. The company has a notice of allowance covering RenovoCath/TAMP targeted-delivery methods, and it reported a first commercial sarcoma use at CARTI. That broadens the longer-run platform narrative beyond pancreatic cancer. This is another one that I intend to hold until readout. May add before then on any weakness after recent move to above $2. Has great potential, imo, for early buyout and expansion beyond the original pancreatic cancer use.

$RNXT 4 times average daily volume already with the stock up nicely. Maybe there is news on the way.

$RNXT Exactly what I’ve been waiting for. Chopping higher regardless of all the market fud and nonsense. Hopefully we stay immune to all the political BS. 🦾🔥🦾🔥

$RNXT the stock is acting differently than it has in the past. Before, good news was met with a falling stock price. And the stock would continue to fall slightly until it was in below a dollar. This time we had good news and the stock appreciated pretty well. It seems like it wants to go down, but there are buyers here. I think that’s the difference. We have buyers in this company now who see value.

$RNXT My bull case with 12~14 target The bull case for RenovoRx ($RNXT) sets a target price of $12.00 – $14.00, driven by its targeted drug-delivery platform in high-unmet-need oncology. * TAMP Tech (RenovoGem): Proprietary catheter system delivers chemotherapy directly into dense tumors, minimizing systemic toxicity. * Phase 3 TIGRIS Trial: Positive overall survival data in pancreatic cancer (LAPC) serves as the core catalyst for institutional re-rating. * Scalability & M&A: FDA-cleared platform expands to other solid tumors (e.g., bile duct cancer), making $RNXT an attractive buyout candidate for big pharma. * Path to Valuation: Clinical de-risking \rightarrow Commercial partnerships & licensing \rightarrow Market capture.